<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/20058">
<title>MedEspera 2010</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/20058</link>
<description>The 3rd International Medical Congress for Students and Young Doctors, May 19-21, 2010</description>
<items>
<rdf:Seq>
<rdf:li rdf:resource="http://repository.usmf.md:80/xmlui/handle/20.500.12710/20357"/>
<rdf:li rdf:resource="http://repository.usmf.md:80/xmlui/handle/20.500.12710/20331"/>
<rdf:li rdf:resource="http://repository.usmf.md:80/xmlui/handle/20.500.12710/20330"/>
<rdf:li rdf:resource="http://repository.usmf.md:80/xmlui/handle/20.500.12710/20329"/>
</rdf:Seq>
</items>
<dc:date>2026-04-20T12:36:55Z</dc:date>
</channel>
<item rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/20357">
<title>MedEspera: The 3rd International Medical Congress for Students and Young Doctors: abstract book, 2010</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/20357</link>
<description>MedEspera: The 3rd International Medical Congress for Students and Young Doctors: abstract book, 2010
</description>
<dc:date>2010-01-01T00:00:00Z</dc:date>
</item>
<item rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/20331">
<title>Strategy and competence in the pharmaceutical industry</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/20331</link>
<description>Strategy and competence in the pharmaceutical industry
Erhan, Tatiana
How will the drug industry look like in 20 years? Can we get there? How? Of course, it’s&#13;
hard times in every industry these days, but none has anywhere near the inherent contradictions and&#13;
high risks, regulations, technologies, and costs pressing down on every aspect of its business. True&#13;
innovation in this maze is a near miracle. Valued at US$199mln in 2008, Moldova’s pharmaceutical&#13;
market is forecast to increase at a steady CAGR of 9.70% in local currency terms. By 2014, the&#13;
market is expected to top US$387 min at consumer prices. In 10-year forecast period through to 2019,&#13;
market development is likely to accelerate, growing at a CAGR of 10.49% in local currency terms,&#13;
stimulated by economic recovery, healthcare modernization and the expansion of healthcare&#13;
insurance coverage. Generics’ CAGR will be similar to that of the overall market, with patented&#13;
medicines expected to benefit from regulatory improvements and Moldova’s progress towards&#13;
European Union (EU) membership, which will translate into a 2009-2014 CAGR of 18.86% in local currency terms. The pharmaceutical industry is a very unique and spectacular industry, with an&#13;
impressive evolution along the 20th and the beginning of the 21st centuries, as well as facing a&#13;
challenging future. The situation in the industry has spectacularly changed in the past two decades,&#13;
leading to new strategies and new portfolios, especially for the major pharmaceutical companies&#13;
worldwide. We are now confronted with a mature, stable industry, constantly affected by mergers and&#13;
acquisitions, as well as by new scientific discoveries. Therefore, trying to foresee the future of such&#13;
an industry becomes very interesting and challenging at the same time.
</description>
<dc:date>2010-01-01T00:00:00Z</dc:date>
</item>
<item rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/20330">
<title>NMR spectroscopy applied in the identification of organic substances and medicinal drugs</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/20330</link>
<description>NMR spectroscopy applied in the identification of organic substances and medicinal drugs
Danilov, Dorina
NMR spectroscopy is one of the most powerful available for studying the structure of&#13;
molecules and identification of drugs. NMR involves the absorption of radiowaves by the nuclei of&#13;
some combined atoms in a molecule that is located in the magnetic field. An NMR spectrum is&#13;
acquired by varying or sweeping the magnetic field over a small range while observing the resonance&#13;
signal from the sample. Due to NMR spectra we can confir the structure of compounds . Aims : The&#13;
purpose of our investigation was to elaborate the method of interpreting 1H proton and 13C carbonic&#13;
spectra. Materials and methods: In the analysis were used the drugs like aspirin „Benzituron ,&#13;
Isohydrofural , Metiferon. The NMR spectra was registered at Fourier Transformation NMR&#13;
spectrometer. The substances were dried for 2 hours at 1050 C, after that the samples is necessary to&#13;
be dissolved in the deuterised water and be filtered through Millipore filter 0.2 pm under vacuum.&#13;
The obtained solutions were transferred in glass tubes about 15 cm in long and 5 mm in diameter .As&#13;
a reference standard is used TMS with the absorbance set at 0,0 ppm ,which is introduced in the tube&#13;
with solution. Results: The NMR spectra of these substances give important and detailed information&#13;
about molecules. Every spectrum is characterized by the chemical shift of peaks and spin-spin&#13;
splitting of peaks . For example the chemical shift indicates the functional groups that are present,&#13;
such as aromatics, ketones, amines, alcohols, aldehyde and so on. .The multiplicity of the resonances&#13;
identifies the type of protons. The 1H protonic spectrum of Benzituron contain resonance signals of a&#13;
high intensity which demonstrate the presence of hydrogen proton in the molecule. The signal at 3.4&#13;
ppm belong to metylen group (-CH2-) it is a diplet. The zone of resonance at 4.56 ppm correspond to&#13;
amines group (NH2) and imines (NH),its represented as a common signal, due to superposition of&#13;
peaks. The signal at 7.21,7.22;7.24; ppm included in multiplet are assigned to aromatic ring.&#13;
Conclusions: There were examined the 1H -protonic and 13C- carbonic spectra of different&#13;
substances in order to elaborate the rules for interpreting spectra. These spectra permits to confirm the&#13;
structure of compounds, to identify the drugs.
</description>
<dc:date>2010-01-01T00:00:00Z</dc:date>
</item>
<item rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/20329">
<title>Robustness testing of a modified-release tablet formulation comprising metformin and glibenclamide</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/20329</link>
<description>Robustness testing of a modified-release tablet formulation comprising metformin and glibenclamide
Potur, Roxana-Georgiana; Antonesi, Ioana; Moisuc, Lacramioara; Axinte, Mihaela
It was recently ascertained that sulphonylureas and biguanides synergistically act for the&#13;
control of blood glucose levels in patients with type II diabetes, by different pharmacological&#13;
mechanisms. The aim of this study is to design a modified release formulation comprising metformin&#13;
hydrochloride and glibenclamide, where one drug does not affect the release of the other drug. Due to&#13;
a relatively high unit dose of metformin, the tablets should be size fitted for oral administration and&#13;
should ensure the controlled release of the two active ingredients. Taking into consideration the poor&#13;
flowability of metformin hydrochloride, in order to attain dose uniformity, a wet granulation&#13;
manufacturing process was used. Glibenclamide was geometrically dispersed into the granules of&#13;
metformin. The mixture was blended with soluble filler, a hydrophilic polymer, a desintegrant and a&#13;
lubricant. The hydrophilic polymer used was: hydroxypropylcellulose (Klucel® HF, HXF) and&#13;
hydroxymethylpropylcellulose (Methocel® K100 LV CR, K4M and E4M). The matrix tablets were&#13;
evaluated for their robustness: hardness, friability, thickness, and weight variation and disintegration&#13;
time. It was concluded that satisfactory robustness profiles can be achieved using all types of&#13;
hydrophilic polymers, by wet granulation of the major active ingredient, followed by a direct&#13;
compression into a modified release matrix. Keywords: metformin hydrochloride, glibenclamide,&#13;
diabetes, formulation, matrix tablets.
</description>
<dc:date>2010-01-01T00:00:00Z</dc:date>
</item>
</rdf:RDF>
